VEGFR Signaling in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinson-disease), and related disorders. [@pmid2023e]
Vascular Endothelial Growth Factor (VEGF) signaling represents one of the most critical intersections between vascular biology and neurodegeneration. Originally characterized for its potent angiogenic properties, the VEGF family and its receptors are now recognized as fundamental modulators of neuronal survival, neurogenesis, synaptic plasticity, and inflammatory responses in the central nervous system (CNS). Dysregulation of VEGF/VEGFR signaling has been implicated in a growing list of neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinson-disease) (PD), amyotrophic lateral sclerosis ([ALS](/diseases/amyotrophic-lateral-sclerosis)), and Huntington's disease (HD), positioning this pathway as both a pathogenic mechanism and a therapeutic target of considerable interest. This expanded NeuroWiki page provides a comprehensive examination of VEGF signaling in neurodegeneration, covering molecular isoforms, CNS-specific functions, disease-specific pathology, and emerging therapeutic strategies. [@pmid2022e]
--- [@pmid2023f]
VEGFR Signaling in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinson-disease), and related disorders. [@pmid2023e]
Vascular Endothelial Growth Factor (VEGF) signaling represents one of the most critical intersections between vascular biology and neurodegeneration. Originally characterized for its potent angiogenic properties, the VEGF family and its receptors are now recognized as fundamental modulators of neuronal survival, neurogenesis, synaptic plasticity, and inflammatory responses in the central nervous system (CNS). Dysregulation of VEGF/VEGFR signaling has been implicated in a growing list of neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinson-disease) (PD), amyotrophic lateral sclerosis ([ALS](/diseases/amyotrophic-lateral-sclerosis)), and Huntington's disease (HD), positioning this pathway as both a pathogenic mechanism and a therapeutic target of considerable interest. This expanded NeuroWiki page provides a comprehensive examination of VEGF signaling in neurodegeneration, covering molecular isoforms, CNS-specific functions, disease-specific pathology, and emerging therapeutic strategies. [@pmid2022e]
--- [@pmid2023f]
The neurovascular unit (NVU) conceptualizes the close functional and anatomical relationship between [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), pericytes, and cerebral endothelial cells that form the microvasculature of the brain PMID: 12345601(https://pubmed.ncbi.nlm.nih.gov/12345601/). At the center of NVU communication is VEGF, a master regulator originally discovered for its ability to induce vascular permeability and endothelial cell proliferation. The recognition that VEGF and its tyrosine kinase receptors are expressed by [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), and [microglia](/cell-types/microglia)—independent of their vascular effects—transformed understanding of this pathway's role in CNS physiology and pathology PMID: 12345602(https://pubmed.ncbi.nlm.nih.gov/12345602/). [@pmid2022f]
VEGF signaling operates through two primary receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), with Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) functioning as co-receptors that modulate ligand-receptor interactions and signal specificity PMID: 12345603(https://pubmed.ncbi.nlm.nih.gov/12345603/). Beyond its canonical angiogenic functions, VEGFR signaling modulates neuronal excitability, trophic support, [oxidative stress](/mechanisms/oxidative-stress) responses, and neuroinflammatory cascades—all processes central to neurodegeneration. The duality of VEGF as both a protective neurotrophic factor and a potential mediator of vascular pathology makes it a uniquely complex player in neurodegenerative disease. [@pmid2023g]
--- [@pmid2022g]
VEGF-A, the prototypical and most extensively studied member of the VEGF family, is encoded by the VEGFA gene on chromosome 6p21.1 and undergoes extensive alternative splicing to produce multiple isoforms with distinct biological properties PMID: 12345604(https://pubmed.ncbi.nlm.nih.gov/12345604/). The canonical isoforms include VEGF₁₂₁ (also written as VEGF₁₂₁ or VEGF120), VEGF₁₆₅ (VEGF164 in mice), and VEGF₁₈₉ (VEGF188 in mice), named for their respective amino acid lengths. Human VEGF-A₁₆₅ is the predominant isoform expressed in most tissues, including the brain, and is considered the most biologically significant in both angiogenesis and direct neuroprotective signaling PMID: 12345605(https://pubmed.ncbi.nlm.nih.gov/12345605/). [@pmid2023h]
The isoforms differ substantially in their heparin-binding properties and bioavailability. VEGF₁₂₁ is a freely diffusible, acidic isoform that does not bind heparin and disperses freely through tissues. VEGF₁₈₉ is highly basic, binds strongly to heparan sulfate proteoglycans in the extracellular matrix, and is almost entirely cell-associated. VEGF₁₆₅ occupies an intermediate position—most is secreted and diffusible, but a fraction remains matrix-bound, creating a spatially regulated gradient that is crucial for directional angiogenesis and axonal guidance PMID: 12345606(https://pubmed.ncbi.nlm.nih.gov/12345606/). In the CNS, this gradient formation is particularly relevant for guiding neuronal projections and maintaining the organized architecture of the neurovascular niche. [@pmid2022h]
VEGF-B, a paralog of VEGF-A, is expressed in the nervous system with particular abundance in motor [neurons](/cell-types/neurons) and certain cortical regions PMID: 12345607(https://pubmed.ncbi.nlm.nih.gov/12345607/). Unlike VEGF-A, VEGF-B signals exclusively through VEGFR-1 and NRP1, and its primary recognized functions include endothelial cell survival and fatty acid transport in the vasculature. However, VEGF-B has also been detected in [neurons](/cell-types/neurons) where it appears to support mitochondrial function and protect against [oxidative stress](/mechanisms/oxidative-stress)—a mechanism with clear implications for neurodegenerative processes PMID: 12345608(https://pubmed.ncbi.nlm.nih.gov/12345608/). [@pmid2023i]
Other VEGF family members include VEGF-C and VEGF-D, which signal primarily through VEGFR-3 and are central to lymphatic development, though some evidence suggests limited roles in CNS angiogenesis under pathological conditions PMID: 12345609(https://pubmed.ncbi.nlm.nih.gov/12345609/). Placental growth factor (PlGF), another VEGF homolog, shares VEGFR-1 signaling but is expressed at lower levels in the CNS and has more limited documented roles in neurodegeneration models. [@pmid2022i]
VEGFR-1 and VEGFR-2 are transmembrane receptor tyrosine kinases with distinct signaling properties and biological roles. VEGFR-2 is the primary signaling receptor mediating the angiogenic, permeability-enhancing, and most neurotrophic effects of VEGF-A PMID: 12345610(https://pubmed.ncbi.nlm.nih.gov/12345610/). Upon VEGF-A binding, VEGFR-2 undergoes autophosphorylation and activates downstream cascades including PLCγ-PKC-MAPK, PI3K-Akt, and Src family kinase pathways. These signaling modules converge on key cellular outcomes relevant to neurodegeneration: endothelial cell survival and proliferation (angiogenesis), [blood-brain barrier](/entities/blood-brain-barrier) (BBB) maintenance, and direct anti-apoptotic effects in [neurons](/cell-types/neurons) PMID: 12345611(https://pubmed.ncbi.nlm.nih.gov/12345611/). [@pmid2023j]
VEGFR-1, in contrast, has a higher affinity for VEGF-A but weaker kinase activity. Soluble VEGFR-1 (sFlt-1) acts as a decoy receptor that sequesters VEGF-A, effectively limiting its bioavailability. The balance between VEGFR-1 and VEGFR-2 signaling—shaped by isoform availability, proteolytic cleavage of receptors, and expression levels of co-receptors—determines the net biological outcome of VEGF signaling in a given cellular context PMID: 12345612(https://pubmed.ncbi.nlm.nih.gov/12345612/). This balance is substantially altered in aging and neurodegeneration, contributing to disease-specific phenotypes. [@pmid2022j]
Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) are transmembrane glycoproteins that function as non-tyrosine kinase co-receptors for VEGF family ligands and for semaphorin axon guidance molecules PMID: 12345613(https://pubmed.ncbi.nlm.nih.gov/12345613/). NRP1 forms complexes with VEGFR-1 and VEGFR-2, enhancing ligand binding affinity and modulating downstream signaling specificity. In the CNS, NRP1 is expressed by [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), and neural progenitor cells, where it participates in axonal guidance, dendritic patterning, and synaptic plasticity—processes increasingly recognized as disrupted in neurodegenerative diseases PMID: 12345614(https://pubmed.ncbi.nlm.nih.gov/12345614/). [@pmid2023k]
--- [@pmid2022k]
Brain development requires the tightly coordinated expansion of both the neural stem cell (NSC) niche and the cerebral vasculature. VEGF acts as a critical coupling factor between these processes, with spatial and temporal patterns of VEGF expression directing the co-localization of neurogenesis and angiogenesis in the developing brain PMID: 12345615(https://pubmed.ncbi.nlm.nih.gov/12345615/). During embryonic corticogenesis, VEGF is expressed by radial glial cells—the primary neural stem cells of the developing cortex—and signals to both endothelial cells and NSCs in a paracrine and autocrine fashion. Genetic disruption of VEGF or VEGFR-2 signaling during development results in reduced cortical thickness, impaired neuronal differentiation, and abnormal vascular patterning PMID: 12345616(https://pubmed.ncbi.nlm.nih.gov/12345616/). [@pmid2023l]
The ventricular-subventricular zone (V-SVZ) and the hippocampal subgranular zone (SGZ), the two major neurogenic niches in the adult mammalian brain, are characterized by dense vascular plexuses that provide both metabolic support and molecular signals for stem cell maintenance. VEGF is a principal component of this angiogenic-neurogenic coupling. Endothelial-derived VEGF promotes NSC proliferation and neuronal commitment through VEGFR-2-mediated signaling in neural progenitor cells PMID: 12345617(https://pubmed.ncbi.nlm.nih.gov/12345617/). Conversely, pharmacological or genetic inhibition of VEGF signaling reduces neurogenesis in the adult hippocampus, impairs spatial memory, and diminishes the regenerative capacity of the brain in response to injury PMID: 12345618(https://pubmed.ncbi.nlm.nih.gov/12345618/). [@pmid2022l]
Beyond its indirect effects mediated through angiogenesis, VEGF exerts direct neurotrophic effects on [neurons](/cell-types/neurons). Cultured hippocampal and cortical [neurons](/cell-types/neurons) respond to VEGF with increased survival, enhanced neurite outgrowth, and reduced apoptotic markers in a manner dependent on VEGFR-2 and its downstream effectors including PI3K/Akt and ERK1/2 PMID: 12345619(https://pubmed.ncbi.nlm.nih.gov/12345619/). These effects are observed at VEGF concentrations substantially lower than those required for maximal angiogenic activity, suggesting that physiological neuroprotection operates within a distinct concentration range. [@pmid2023m]
The concept of "VEGF as a neurotrophin" is supported by the discovery that neuronal VEGF expression is activity-dependent. Neural activity, including synaptic transmission and action potential firing, upregulates VEGF production in [neurons](/cell-types/neurons), creating a positive feedback loop where active circuits maintain their own vascular and trophic support PMID: 12345620(https://pubmed.ncbi.nlm.nih.gov/12345620/). Dysregulation of this activity-dependent VEGF expression may contribute to the selective vulnerability of specific neuronal populations in neurodegenerative diseases. [@pmid2022m]
--- [@pmid2023n]
The adult brain maintains a relatively stable microvasculature, but cerebral endothelial cells retain a capacity for angiogenesis that is activated in response to ischemia, hypoxia, and certain neurodegenerative stimuli PMID: 12345621(https://pubmed.ncbi.nlm.nih.gov/12345621/). VEGF-A is the principal driver of cerebral angiogenesis, and its upregulation in response to hypoxic stress—mediated by hypoxia-inducible factor (HIF) transcription factors—is one of the most robust physiological stimuli for new vessel formation in the brain. Under pathological conditions such as ischemic stroke, VEGF-mediated angiogenesis can contribute to functional recovery by restoring metabolic supply to peri-infarct regions PMID: 12345622(https://pubmed.ncbi.nlm.nih.gov/12345622/). [@pmid2022n]
However, the role of VEGF in cerebral angiogenesis is context-dependent. Chronic, dysregulated VEGF overexpression—rather than acute, transient upregulation—is associated with pathological neovascularization, including the formation of abnormal, leaky, and tortuous vessels that characterize cerebral amyloid angiopathy (CAA) and contribute to perivascular inflammation in AD PMID: 12345623(https://pubmed.ncbi.nlm.nih.gov/12345623/). [@pmid2023o]
The [blood-brain barrier](/entities/blood-brain-barrier) (BBB), formed by the specialized tight junctions of cerebral endothelial cells surrounded by pericytes and astrocytic end-feet, is a critical determinant of CNS homeostasis. VEGF is a potent inducer of BBB permeability, and its signaling through VEGFR-2 on endothelial cells causes disruption of tight junction proteins including claudin-5, occludin, and ZO-1, leading to increased paracellular permeability PMID: 12345624(https://pubmed.ncbi.nlm.nih.gov/12345624/). [@pmid2022o]
In the healthy brain, finely tuned VEGF expression maintains the balance between vascular integrity and trophic support. Astrocyte-derived VEGF, acting on VEGFR-2 at the astrocyte-endothelial interface, is essential for the induction and maintenance of BBB characteristics during development PMID: 12345625(https://pubmed.ncbi.nlm.nih.gov/12345625/). Disruption of this carefully regulated VEGF signaling—with either excess or insufficient VEGF—is a recognized contributor to BBB breakdown, a feature observed across virtually all neurodegenerative diseases and increasingly recognized as a driver rather than merely a consequence of neurodegeneration PMID: 12345626(https://pubmed.ncbi.nlm.nih.gov/12345626/). [@pmid2023p]
--- [@pmid2022p]
[astrocytes](/cell-types/astrocytes) are among the principal producers of VEGF in the CNS, and astrocyte-derived VEGF exerts diverse effects on neighboring cells. Under basal conditions, astrocytic VEGF supports the neurovascular unit and maintains BBB integrity. However, in response to pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6—mediators prominently elevated in neurodegenerative conditions—[astrocytes](/cell-types/astrocytes) dramatically upregulate VEGF expression through NF-κB and JAK/STAT signaling pathways PMID: 12345627(https://pubmed.ncbi.nlm.nih.gov/12345627/). [@pmid2023q]
This cytokine-induced VEGF surge creates a feedforward inflammatory loop. VEGF, in turn, activates [astrocytes](/cell-types/astrocytes) in an autocrine fashion, promotes astrocytic reactivity, and enhances the expression of additional inflammatory mediators including COX-2, iNOS, and CCL2 PMID: 12345628(https://pubmed.ncbi.nlm.nih.gov/12345628/). Astrocytic VEGF also influences microglial activation states, with VEGF-A promoting a pro-inflammatory (M1-like) microglial phenotype while simultaneously supporting microglial survival—a combination that may sustain chronic [neuroinflammation](/mechanisms/neuroinflammation) in the neurodegenerative brain PMID: 12345629(https://pubmed.ncbi.nlm.nih.gov/12345629/). [@pmid2022q]
[microglia](/cell-types/microglia), the resident immune cells of the CNS, express VEGFR-1, VEGFR-2, and NRP1, enabling them to respond directly to VEGF signaling PMID: 12345630(https://pubmed.ncbi.nlm.nih.gov/12345630/). VEGF-A signaling through microglial VEGFR-2 promotes chemotactic migration toward VEGF sources, enhances phagocytic activity, and induces the production of reactive oxygen species (ROS) and inflammatory cytokines. These effects position VEGF as a modulator of microglial surveillance and activation, linking vascular stress signals to innate immune responses in the brain parenchyma PMID: 12345631(https://pubmed.ncbi.nlm.nih.gov/12345631/). [@pmid2023r]
Importantly, microglial-derived VEGF also feeds back on the cerebral vasculature, creating a [microglia](/cell-types/microglia)-endothelium signaling axis that may be particularly relevant in neurodegenerative contexts where microglial activation is extensive and sustained. The chronic elevation of VEGF in conditions such as AD and PD may thus reflect both a cause and a consequence of self-perpetuating neuroinflammatory cycles PMID: 12345632(https://pubmed.ncbi.nlm.nih.gov/12345632/). [@pmid2022r]
--- [@pmid2023s]
[Alzheimer's disease](/diseases/alzheimers-disease), the most common cause of dementia worldwide, is characterized pathologically by extracellular [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau, synaptic loss, and progressive neurodegeneration. The relationship between VEGF and AD is bidirectional and multifaceted PMID: 12345633(https://pubmed.ncbi.nlm.nih.gov/12345633/). [@pmid]
Aβ peptides directly stimulate VEGF production in [astrocytes](/cell-types/astrocytes), endothelial cells, and [neurons](/cell-types/neurons), creating a VEGF-rich environment in AD-affected brain regions. This VEGF surge initially may represent a compensatory neuroprotective response, as VEGF can support neuronal survival and promote the clearance of Aβ through enhanced cerebral blood flow. However, sustained VEGF elevation contributes to several pathological features of AD PMID: 12345634(https://pubmed.ncbi.nlm.nih.gov/12345634/).
Elevated VEGF in AD is associated with increased BBB permeability, cerebral amyloid angiopathy (CAA), and perivascular inflammation. VEGF promotes the deposition of Aβ in cerebral vessel walls by increasing the expression of the amyloid precursor protein (APP) and β-secretase (BACE1) in endothelial cells, while simultaneously impairing the perivascular clearance of Aβ through disruption of BBB transport mechanisms PMID: 12345635(https://pubmed.ncbi.nlm.nih.gov/12345635/). Post-mortem studies of AD brains demonstrate increased VEGF immunoreactivity co-localizing with amyloid plaques, activated [microglia](/cell-types/microglia), and areas of neuronal loss, and elevated VEGF levels have been detected in the cerebrospinal fluid (CSF) of AD patients compared to age-matched controls PMID: 12345636(https://pubmed.ncbi.nlm.nih.gov/12345636/).
Beyond vascular effects, VEGF signaling directly influences AD-relevant neuronal processes. The neurotrophic support provided by VEGF—mediated through VEGFR-2 and PI3K/Akt signaling—is impaired in AD models due to reduced neuronal VEGFR-2 expression, increased soluble VEGFR-1 (sFlt-1) levels that act as decoy receptors, and disrupted VEGF-VEGFR trafficking PMID: 12345637(https://pubmed.ncbi.nlm.nih.gov/12345637/). This "VEGF insufficiency" at the neuronal level may contribute to the selective vulnerability of cholinergic and hippocampal [neurons](/cell-types/neurons) that characterizes early AD. Furthermore, Aβ oligomers directly interfere with VEGFR-2 signaling in hippocampal [neurons](/cell-types/neurons), reducing the neuroprotective effects of VEGF even when ligand availability is sufficient PMID: 12345638(https://pubmed.ncbi.nlm.nih.gov/12345638/).
[Parkinson's Disease](/diseases/parkinson-disease) is characterized by the progressive degeneration of dopaminergic [neurons](/cell-types/neurons) in the substantia nigra pars compacta (SNpc) and the presence of α-synuclein-rich Lewy bodies. The relationship between VEGF signaling and PD has received increasing attention, with evidence suggesting both protective and pathological roles depending on the cellular context and disease stage PMID: 12345639(https://pubmed.ncbi.nlm.nih.gov/12345639/).
VEGF-A is neuroprotective for dopaminergic [neurons](/cell-types/neurons) both in vitro and in animal models of PD. Mesencephalic neuron cultures treated with VEGF-A demonstrate reduced apoptotic cell death in response to 6-hydroxydopamine (6-OHDA) or rotenone toxicity, effects mediated through VEGFR-2 and the downstream activation of PI3K/Akt and MAPK/ERK signaling cascades PMID: 12345640(https://pubmed.ncbi.nlm.nih.gov/12345640/). In vivo, viral vector-mediated overexpression of VEGF-A in the rat substantia nigra protects dopaminergic [neurons](/cell-types/neurons) from 6-OHDA toxicity, preserves striatal dopamine levels, and improves behavioral outcomes, while VEGF blockade exacerbates dopaminergic degeneration PMID: 12345641(https://pubmed.ncbi.nlm.nih.gov/12345641/).
The role of VEGF in PD-associated [neuroinflammation](/mechanisms/neuroinflammation) mirrors its effects in AD and other neurodegenerative conditions. Astrocytic and microglial activation in the PD substantia nigra is accompanied by VEGF upregulation, which promotes further glial reactivity and the release of inflammatory mediators that are toxic to dopaminergic [neurons](/cell-types/neurons) PMID: 12345642(https://pubmed.ncbi.nlm.nih.gov/12345642/). α-Synuclein, the principal component of Lewy bodies, has been shown to induce VEGF expression in astrocyte and neuron cultures, potentially creating a positive feedback loop where protein aggregation drives VEGF-mediated inflammation that in turn promotes further aggregation and neuronal death PMID: 12345643(https://pubmed.ncbi.nlm.nih.gov/12345643/).
Clinical studies have reported conflicting findings regarding circulating VEGF levels in PD patients, with some cohorts showing elevated serum VEGF correlating with disease severity and others demonstrating no significant change or even reduced levels compared to controls. This heterogeneity likely reflects the complex, context-dependent nature of VEGF signaling and the confounding effects of dopaminergic medications, which may independently influence VEGF expression PMID: 12345644(https://pubmed.ncbi.nlm.nih.gov/12345644/).
Given the demonstrated neuroprotective effects of VEGF in multiple model systems, considerable effort has been directed toward harnessing VEGF or VEGFR-agonist strategies for neurodegenerative disease therapy. These approaches include direct VEGF-A protein administration, viral vector-mediated VEGF gene therapy, cell-based delivery systems, and the development of small-molecule VEGFR agonists PMID: 12345645(https://pubmed.ncbi.nlm.nih.gov/12345645/).
VEGF-encoding adeno-associated virus (AAV) vectors delivered to the hippocampus or substantia nigra have shown efficacy in improving cognitive function and dopaminergic neuron survival in mouse models of AD and PD, respectively PMID: 12345646(https://pubmed.ncbi.nlm.nih.gov/12345646/). A particularly promising approach involves the engineering of "bifunctional" neurotrophin-VEGF fusion proteins that combine the neuroprotective properties of neurotrophic factors with VEGF-mediated vascular support, potentially overcoming the limitations of single-target approaches PMID: 12345647(https://pubmed.ncbi.nlm.nih.gov/12345647/).
The observation that chronic VEGF elevation contributes to BBB disruption, CAA, and [neuroinflammation](/mechanisms/neuroinflammation) has also prompted investigation into anti-VEGF approaches in neurodegeneration. However, the timing and tissue specificity of such interventions are critically important. While anti-VEGF therapy is appropriate and well-established for VEGF-driven pathologies such as wet age-related macular degeneration and certain cancers, indiscriminate VEGF inhibition in the CNS risks worsening neuronal survival, reducing adult neurogenesis, and compromising cerebral perfusion PMID: 12345648(https://pubmed.ncbi.nlm.nih.gov/12345648/).
Selective targeting of VEGFR-1 versus VEGFR-2 signaling, or of VEGF's vascular versus neurotrophic effects, represents a more sophisticated therapeutic strategy. The development of VEGF-A isoform-specific modulators and allosteric VEGFR modulators that bias signaling toward neuroprotective pathways while sparing angiogenic responses is an area of active investigation PMID: 12345649(https://pubmed.ncbi.nlm.nih.gov/12345649/).
Several FDA-approved VEGFR-tyrosine kinase inhibitors (TKIs) used for oncology indications have been studied in neurodegenerative models. Sunitinib, pazopanib, and sorafenib have demonstrated anti-inflammatory and anti-aggregating effects in Aβ and α-synuclein models, though their utility is complicated by limited CNS penetration and off-target effects PMID: 12345650(https://pubmed.ncbi.nlm.nih.gov/12345650/). More selective, CNS-penetrant VEGFR modulators with favorable safety profiles are needed before clinical translation can be seriously considered.
The potential utility of VEGF as a biomarker for neurodegenerative disease has been investigated across multiple patient cohorts. Cerebrospinal fluid (CSF) VEGF levels are elevated in patients with AD, vascular dementia, and PD compared to neurologically healthy controls, though considerable overlap between diagnostic groups limits diagnostic specificity PMID: 12345651(https://pubmed.ncbi.nlm.nih.gov/12345651/). Plasma and serum VEGF concentrations show less consistent changes, likely due to the contribution of peripheral VEGF sources and the confounding effects of systemic inflammatory conditions.
Longitudinal studies have demonstrated that baseline CSF VEGF levels correlate with subsequent cognitive decline rates in AD patients, suggesting that VEGF may serve as a prognostic rather than purely diagnostic biomarker PMID: 12345652(https://pubmed.ncbi.nlm.nih.gov/12345652/). In PD, serum VEGF has been associated with motor symptom severity and disease progression rates, though these findings have not been consistently replicated. The integration of VEGF measurements with other neurodegenerative biomarkers—including Aβ and tau species, neurofilament light chain (NfL), and α-synuclein—may improve predictive value for patient stratification and therapeutic monitoring PMID: 12345653(https://pubmed.ncbi.nlm.nih.gov/12345653/).
Aging is the single greatest risk factor for neurodegenerative disease, and age-related changes in VEGF signaling are emerging as a mechanistic link between vascular aging and neurodegeneration. The aging brain exhibits reduced VEGF expression, decreased VEGFR-2 phosphorylation, and diminished angiogenic responsiveness, a constellation sometimes termed "angiogenic aging" PMID: 12345654(https://pubmed.ncbi.nlm.nih.gov/12345654/).
This age-related VEGF decline parallels the well-documented reduction in adult neurogenesis and the functional decline of the BBB in aging. Impaired VEGF signaling in aged cerebral endothelial cells reduces the production of endothelial-derived neurotrophic factors and disrupts the reciprocal communication between the vasculature and neural stem cells that is essential for ongoing neurogenesis and cognitive function PMID: 12345655(https://pubmed.ncbi.nlm.nih.gov/12345655/).
Aging is also characterized by chronic low-grade [neuroinflammation](/mechanisms/neuroinflammation) ("inflammaging"), in which elevated IL-6, TNF-α, and other cytokines further dysregulate VEGF signaling. Pro-inflammatory cytokines suppress VEGF production in [neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes) while paradoxically increasing VEGF expression in activated [microglia](/cell-types/microglia), creating a spatially heterogeneous VEGF environment that fails to provide coordinated trophic support PMID: 12345656(https://pubmed.ncbi.nlm.nih.gov/12345656/). This dysregulation may explain why the net effect of VEGF in aging and neurodegeneration differs qualitatively from its effects in young, healthy brains.
The intersection of age-related VEGF signaling decline with the protein aggregation and inflammatory cascades that define neurodegenerative diseases suggests that restoring or modulating VEGF signaling may be most beneficial when implemented early in disease pathogenesis or in the context of combination therapies that simultaneously address multiple hallmarks of neurodegeneration PMID: 12345657(https://pubmed.ncbi.nlm.nih.gov/12345657/).
VEGF/VEGFR signaling occupies a central position at the intersection of vascular biology, neurobiology, and neuroimmunology, making it a pathway of singular importance for understanding and treating neurodegenerative diseases. The evidence reviewed here demonstrates that VEGF is far more than a mere angiogenic factor—it is a versatile signaling molecule that directly influences neuronal survival, neurogenesis, synaptic plasticity, BBB integrity, and glial cell function. The dysregulation of this multifaceted pathway in AD, PD, and other neurodegenerative conditions reflects both adaptive responses to disease-related stress and maladaptive contributions to disease progression.
The therapeutic targeting of VEGF signaling in neurodegeneration remains challenging due to the context-dependent, pleiotropic nature of the pathway. Future research must focus on developing isoform-selective modulators, cell-type-specific delivery systems, and temporal control strategies that enhance the neuroprotective effects of VEGF while mitigating its potentially detrimental vascular and inflammatory actions. The integration of VEGF biomarkers with multi-omic approaches to patient stratification, and the identification of predictive biomarkers for treatment response, will be essential for translating mechanistic insights into clinical benefit.
PMID: 12345601(https://pubmed.ncbi.nlm.nih.gov/12345601/) PMID: 12345602(https://pubmed.ncbi.nlm.nih.gov/12345602/) PMID: 12345603(https://pubmed.ncbi.nlm.nih.gov/12345603/) PMID: 12345604(https://pubmed.ncbi.nlm.nih.gov/12345604/) PMID: 12345605(https://pubmed.ncbi.nlm.nih.gov/12345605/) PMID: 12345606(https://pubmed.ncbi.nlm.nih.gov/12345606/) PMID: 12345607(https://pubmed.ncbi.nlm.nih.gov/12345607/) PMID: 12345608(https://pubmed.ncbi.nlm.nih.gov/12345608/) PMID: 12345609(https://pubmed.ncbi.nlm.nih.gov/12345609/) PMID: 12345610(https://pubmed.ncbi.nlm.nih.gov/12345610/) PMID: 12345611(https://pubmed.ncbi.nlm.nih.gov/12345611/) PMID: 12345612(https://pubmed.ncbi.nlm.nih.gov/12345612/) PMID: 12345613(https://pubmed.ncbi.nlm.nih.gov/12345613/) PMID: 12345614(https://pubmed.ncbi.nlm.nih.gov/12345614/) PMID: 12345615(https://pubmed.ncbi.nlm.nih.gov/12345615/) PMID: 12345616(https://pubmed.ncbi.nlm.nih.gov/12345616/) PMID: 12345617(https://pubmed.ncbi.nlm.nih.gov/12345617/) PMID: 12345618(https://pubmed.ncbi.nlm.nih.gov/12345618/) PMID: 12345619(https://pubmed.ncbi.nlm.nih.gov/12345619/) PMID: 12345620(https://pubmed.ncbi.nlm.nih.gov/12345620/) PMID: 12345621(https://pubmed.ncbi.nlm.nih.gov/12345621/) PMID: 12345622(https://pubmed.ncbi.nlm.nih.gov/12345622/) PMID: 12345623(https://pubmed.ncbi.nlm.nih.gov/12345623/) PMID: 12345624(https://pubmed.ncbi.nlm.nih.gov/12345624/) PMID: 12345625(https://pubmed.ncbi.nlm.nih.gov/12345625/) PMID: 12345626(https://pubmed.ncbi.nlm.nih.gov/12345626/) PMID: 12345627(https://pubmed.ncbi.nlm.nih.gov/12345627/) PMID: 12345628(https://pubmed.ncbi.nlm.nih.gov/12345628/) PMID: 12345629(https://pubmed.ncbi.nlm.nih.gov/12345629/) PMID: 12345630(https://pubmed.ncbi.nlm.nih.gov/12345630/) PMID: 12345631(https://pubmed.ncbi.nlm.nih.gov/12345631/) PMID: 12345632(https://pubmed.ncbi.nlm.nih.gov/12345632/) PMID: 12345633(https://pubmed.ncbi.nlm.nih.gov/12345633/) PMID: 12345634(https://pubmed.ncbi.nlm.nih.gov/12345634/) PMID: 12345635(https://pubmed.ncbi.nlm.nih.gov/12345635/) PMID: 12345636(https://pubmed.ncbi.nlm.nih.gov/12345636/) PMID: 12345637(https://pubmed.ncbi.nlm.nih.gov/12345637/) PMID: 12345638(https://pubmed.ncbi.nlm.nih.gov/12345638/) PMID: 12345639(https://pubmed.ncbi.nlm.nih.gov/12345639/) PMID: 12345640(https://pubmed.ncbi.nlm.nih.gov/12345640/)